Biospective clinical scientist Donald McLaren will present our latest work, how quantitative amyloid imaging can reduce screening numbers and enrollment time in clinical trials, at the 10th Clinical Trials on Alzheimer’s Disease (CTAD) meeting in Boston from November 1st-4th, 2017. Please stop by our poster (P53) on Friday or Saturday to learn more or send us a message by clicking on the logo to setup a meeting.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *